FilingSEC EDGAR6-K
Optimi Health to initiate Phase 2 clinical trial for psilocybin-assisted therapy
· SEC accepted
StagePhase 2
Filing content
The company plans to initiate a Phase 2 clinical trial for psilocybin-assisted therapy in MDD patients in the first half of 2027, with Health Canada authorization for up to 200 participants.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…